# Flexible-Dose Trial in Early Parkinson's Disease (PD)

> **NCT04223193** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 304 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Tavapadon
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04223193
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-06
- **Primary completion:** 2024-10-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04223193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04223193, "Flexible-Dose Trial in Early Parkinson's Disease (PD)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04223193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*